Eris Lifesciences Ltd

Eris Lifesciences Ltd

Eris Lifesciences Ltd has announced the re-appointment of Mr. Sujesh Vasudevan as Independent Director of the Company for a period of 5 years from July 25, 2027 to July 24, 2032, and the convening of the 20th Annual General Meeting on September 25, 2026.

Eris Lifesciences Ltd

Eris Lifesciences Ltd has announced an analyst/institutional investor meeting with HBM Partners AG on August 27, 2026, to discuss publicly available documents.

Eris Lifesciences Ltd

Eris Lifesciences Ltd has announced an analyst/institutional investor meeting on August 17, 2026, where the management will discuss publicly available documents and no unpublished price-sensitive information will be disclosed.

Eris Lifesciences Ltd

Eris Lifesciences Ltd has informed the exchanges about an upcoming investor conference, where the company's management will interact with investors and discuss publicly available documents. The meeting is scheduled for August 14, 2026, and will be held virtually.

Eris Lifesciences Ltd

Eris Lifesciences Ltd has drawn down a working capital term loan of ₹64,40,00,000 from Axis Bank Limited to meet other short-term liabilities. The aggregate debt level of the company remains unchanged.

Eris Lifesciences Ltd

Eris Lifesciences Ltd has made available the transcript of its analyst and investor call following the announcement of its financial results for the quarter ended June 30, 2026, on its website.

Eris Lifesciences Ltd

Eris Lifesciences Ltd has announced an analyst/institutional investor meeting on August 4, 2026, where the management will discuss publicly available documents and no unpublished price-sensitive information will be shared.

Eris Lifesciences Ltd

Eris Lifesciences Ltd has informed about the allotment of 4,816 equity shares at a premium of Rs. 450.04 per share under the ESOP-2017 Scheme, increasing the paid-up share capital from Rs. 13,85,78,489 to Rs. 13,85,83,305.

Eris Lifesciences Ltd

Eris Lifesciences Ltd has announced the availability of the earnings conference call recording for the quarter ended June 30, 2026, on its website.

Eris Lifesciences Ltd

Eris Lifesciences Ltd reported Q1 FY27 financial highlights, with a 14.2% YoY revenue growth and 14.5% YoY PAT growth. The company's DBF segment saw a 14% organic growth with a 35% EBIDTA margin. Eris also established an early leadership in the GLP-1 market with a 21% unit share and 20% value share. The company's insulin market share increased from 9% to 16% since the Biocon acquisition.

Eris Lifesciences Ltd

Eris Lifesciences Ltd announced its financial results for the quarter ended June 30, 2026, with the company's earnings per share (EPS) and revenue showing a significant improvement compared to the same period last year.

Eris Lifesciences Ltd

Eris Lifesciences Ltd's board meeting outcome was positive, with the company announcing the sale of its subsidiary to a related party, and the sale of its assets to a third party. The meeting also approved the company's financial results for the year ended March 31, 2022.

Eris Lifesciences Ltd

Eris Lifesciences Ltd has announced a conference call for analysts and investors to discuss its unaudited financial results for Q1 FY2027, which will be considered by the Board of Directors on July 29, 2026.

Eris Lifesciences Ltd

Eris Lifesciences Ltd has scheduled a Board of Directors meeting on July 29, 2026, to consider and approve the financial results for the quarter ended June 30, 2026.

Eris Lifesciences Ltd

Eris Lifesciences Ltd released its Corporate Presentation dated June 23, 2026, outlining its strategic direction and performance. The presentation highlights the company's position among the top-20 Indian pharma companies, with a strong focus on super-specialty segments like Anti-Diabetes and Insulins, where it holds significant market shares. It details robust R&D and manufacturing capabilities, alongside an expanding international business across 70+ countries. The company emphasizes its strategy of leveraged acquisitions, with investments exceeding INR 4,300 crore, to enter and strengthen its presence in high-value therapeutic areas such as Dermatology, Nephrology, and Injectables, signaling strong growth prospects.